10-Q: Indaptus Q3 Loss Widens, Cash to Fund Operations into Q1 2026

Indaptus Therapeutics reported an increased net loss for the nine months ended September 30, 2025, while advancing its Decoy20 clinical trials and raising significant capital to extend its cash runway into the first quarter of 2026.

Summary

• Net loss for the nine months ended September 30, 2025, increased to $12.7 million from $10.9 million in the prior year period.
• Research and development expenses rose by 36.1% to $6.5 million for the nine months ended September 30, 2025, driven by higher clinical trial costs for the Phase 1 study.
• General and administrative expenses decreased by 19.3% to $5.2 million for the nine months ended September 30, 2025, primarily due to reduced stock-based compensation and payroll.
• Cash used in operating activities increased to $11.6 million for the nine months ended September 30, 2025, compared to $8.9 million in the same period last year.
• The company held $5.8 million in cash and cash equivalents as of September 30, 2025, which is expected to fund operations into the first quarter of 2026.
• Indaptus completed multiple capital raises totaling approximately $11.7 million in net proceeds during the nine months, including a $5.7 million convertible note private placement, a $1.74 million Standby Equity Purchase Agreement, a $2.25 million private placement, and a $2.34 million At The Market offering.
• A 1-for-28 reverse stock split was effected on June 26, 2025, to regain Nasdaq compliance.
• Enrollment in the Decoy20 monotherapy weekly dosing study was concluded in May 2025 to focus on the combination study with Tislelizumab.
• The combination study with Tislelizumab has enrolled six evaluable participants, with three showing stable disease at the first re-staging assessment, though one later progressed and another discontinued Tislelizumab due to an immune-related adverse event. Enrollment is currently paused.

Sentiment

Score: 3

Explanation: The company faces significant financial challenges, including an increased net loss, higher cash burn, and a 'going concern' warning. While capital raises have extended the cash runway, the pause in the combination clinical trial and mixed efficacy results for some participants indicate ongoing development hurdles and uncertainty. The temporary cost reductions and subsequent discontinuation also suggest financial strain.

Positives

• Successful completion of multiple capital raises, providing approximately $11.7 million in net proceeds during the nine months ended September 30, 2025.
• Decoy20 monotherapy study showed early signs of potential benefits with stable disease in some participants.
• The combination of Decoy20 and Tislelizumab appears tolerable at the current dose and schedule, with three out of six evaluable participants showing stable disease at the first re-staging assessment.
• General and administrative expenses decreased by 32.5% for the three months and 19.3% for the nine months ended September 30, 2025, reflecting cost reduction efforts.
• Regained compliance with Nasdaq minimum bid price requirement following the 1-for-28 reverse stock split.

Negatives

• Net loss increased to $12.7 million for the nine months ended September 30, 2025, from $10.9 million in the prior year.
• Cash used in operating activities significantly increased to $11.6 million for the nine months ended September 30, 2025, indicating a higher burn rate.
• The company has identified conditions that raise substantial doubt about its ability to continue as a going concern.
• Enrollment in the Decoy20 monotherapy weekly dosing study was concluded, and enrollment in the combination study with Tislelizumab is currently paused.
• Three out of six evaluable participants in the combination study experienced disease progression, and one stable disease subject later progressed.
• One participant in the combination study discontinued Tislelizumab due to an immune-related adverse event.
• Other income, net, decreased significantly by 68.7% for the nine months ended September 30, 2025, due to lower cash and cash equivalent balances.

Risks

• The company is a clinical-stage company with a limited operating history, is not currently profitable, and may never become profitable.
• There is substantial doubt regarding the company's ability to continue as a going concern.
• The company will need to raise additional capital, and if unsuccessful, may be forced to delay, limit, or eliminate research programs, product development, and commercialization efforts.
• Raising additional capital would cause dilution to existing shareholders and may restrict operations or require relinquishing rights to technologies or product candidates.
• Clinical and preclinical development involves lengthy and expensive processes with uncertain outcomes, and delays could increase costs or limit revenue generation.
• Product candidates may cause undesirable side effects that could delay or prevent regulatory approval or commercialization.
• Commercial success depends on market acceptance among physicians, patients, healthcare payors, and the medical community.
• Reliance on third parties for preclinical studies, clinical trials, and manufacturing increases risks of delays or insufficient quantities.
• The successful commercialization of Decoy20 depends on governmental authorities and health insurers establishing coverage, adequate reimbursement levels, and favorable pricing policies.
• Unfavorable global economic conditions could adversely affect the business, financial condition, or results of operations and reduce the ability to access capital.
• The market price of common stock is volatile, and investors may sustain a complete loss of their investment.

Future Outlook

The company expects to continue incurring significant research and development expenses and other operating expenses as it ramps up clinical development activities and hires additional personnel. Cash and cash equivalents are projected to fund operations into the first quarter of 2026 based on the current operating plan. The company will need to raise additional capital through equity or debt financings, collaborations, strategic alliances, or license agreements to achieve its business objectives, with no assurance of availability on acceptable terms. The ultimate impact of current macroeconomic conditions on operations and capital access remains highly uncertain.

Management Comments

• We believe that, as of the date of the issuance of these unaudited condensed consolidated financial statements, we have adequate cash to fund our ongoing activities into the first quarter of 2026 based on our current operating plan.
• We plan to execute our operating plan by obtaining additional capital, principally through entering into collaborations, strategic alliances, or license agreements with third parties and/or additional public or private debt and equity financing.
• However, there is no assurance that additional capital and/or financing will be available to the Company, and even if available, whether it will be on terms acceptable to the Company or in the amounts required.
• If we are unsuccessful in securing sufficient financing, we may need to delay, reduce, or eliminate our research and development programs, which could adversely affect our business prospects, or cease operations.
• We have observed early signs of potential benefits emerging with some participants with stable disease [in the Decoy20 monotherapy study].
• The Decoy20 and tislelizumab combination appears to be tolerable at the current dose and schedule.

Industry Context

Indaptus Therapeutics operates in the highly competitive and capital-intensive clinical biotechnology sector, focusing on novel cancer immunotherapy. The shift from monotherapy to combination studies, particularly with checkpoint inhibitors like Tislelizumab, aligns with broader industry trends seeking synergistic effects to improve patient outcomes in advanced solid tumors. The challenges of securing sufficient funding and managing high R&D costs are common for clinical-stage biotechs, especially amidst volatile macroeconomic conditions, which can impact capital access and valuation.

Comparison to Industry Standards

• As a clinical-stage company with no approved products and no revenue from product sales, direct comparison to revenue-generating industry benchmarks is not applicable.
• The company's reliance on external financing and its 'going concern' warning are typical for early-stage biotech companies with high R&D burn rates and no commercial products.
• The observed adverse events like cytokine release syndrome (CRS) in early-stage immunotherapy trials are not uncommon, and their resolution within 24-72 hours suggests manageability, which is a key factor in assessing drug safety profiles in this field.
• The decision to pause enrollment in the combination study to assess efficacy and next development options is a standard practice in clinical development, reflecting a data-driven approach to trial progression.

Corporate Governance

Related Party Transactions

• The Chief Executive Officer of the company participated in the June 2025 private placement of convertible promissory notes.

Stakeholder Impact

• Shareholders: Significant dilution from multiple equity raises and potential future raises; volatility in stock price; risk of complete loss due to 'going concern' doubt; reverse stock split to maintain Nasdaq listing.
• Employees: Temporary reduction of base salaries for certain officers (discontinued Nov 1, 2025); potential for increased headcount in R&D.
• Creditors: Convertible notes issued and converted; ongoing need for financing could impact creditworthiness.
• Patients: Continued development of Decoy20 offers potential new treatment options for advanced solid tumors and lymphomas, but clinical trial pauses and mixed results introduce uncertainty.

Next Steps

• Obtain additional capital through collaborations, strategic alliances, license agreements, or public/private debt and equity financing.
• Conduct additional efficacy evaluations of remaining participants in the Decoy20/Tislelizumab combination study.
• Assess next development options for the Decoy20 program.
• Continue to ramp up clinical development activities and incur expenses associated with hiring additional personnel.
• Potentially incur significant commercialization expenses if any product candidates receive marketing approval.

Key Dates

Recommendation

Indaptus Therapeutics presents a high-risk investment profile. The company reported a widening net loss and a significant increase in cash burn, leading to an explicit 'substantial doubt about its ability to continue as a going concern.' While recent capital raises have extended the cash runway into Q1 2026, this is a very short period, necessitating further dilutive financing. The clinical program, Decoy20, shows mixed results with a pause in the combination study due to disease progression in half of the evaluable participants and an immune-related adverse event in another. This indicates significant hurdles in clinical development. The 1-for-28 reverse stock split, while maintaining Nasdaq compliance, often signals underlying financial distress and can be followed by further price erosion. Given the substantial financial instability, ongoing clinical uncertainties, and the high likelihood of further dilution, a seasoned investor would likely view this as a 'strong sell' due to the significant downside risk and lack of clear positive catalysts.

Keywords

Indaptus Therapeutics, INDP, Biotechnology, Cancer Immunotherapy, Decoy20, Phase 1 Clinical Trial, Solid Tumors, Lymphomas, Tislelizumab, PD-1 Inhibitor, Oncology, Clinical Stage, Going Concern, Capital Raise, SEC Filing, 10-Q, Drug Development, Biopharma